Malignant melanoma: The implications of cost for stakeholder innovation

American Journal of Pharmacy Benefits

Volumn 4, Issue 2, 2012, Pages 66-76

  Styperek, Andrew ^a   Kimball, Alexa Boer ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; DACARBAZINE; IMIQUIMOD; MELPHALAN; METOCLOPRAMIDE; RECOMBINANT INTERLEUKIN 2;

ACCOUNTING; ARTICLE; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISTANT METASTASIS; DRUG COST; DRUG MEGADOSE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; LASER SURGERY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAID; MEDICAL LITERATURE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT MONITORING; PRACTICE GUIDELINE; PRODUCTIVITY; RECURRENT CANCER; SENTINEL LYMPH NODE BIOPSY; SOCIETY; TUMOR BIOPSY; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 84859753179     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005. Based on November 2007 SEER data submission. Bethesda, MD: National Cancer Institute; 2008. http://seer.cancer.gov/csr/1975_2005/. Accessed July 7, 2008.
2. American Cancer Society. Cancer Facts & Figures-2008. Atlanta, GA: American Cancer Society; 2008.
3. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol. 1990;23(2, pt 1):308-310.
4. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38(5, pt 1):669-680.
5. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Arch Dermatol. 2010;146(3):249-256.
6. Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol Online J. 2009;15(11):1.
7. Houghton AN, Colt DG. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Melanoma v.2.2008. Fort Washington, PA: National Comprehensive Cancer Network; 2008.
8. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648.
9. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15(5):1476-1484.
10. Zalla JA. Coping with carriers from copays to collections and claims. AADA Course 104: Coding, Documentation, Practice Management. Presented at: 65th Annual Meeting of the American Academy of Dermatology; February 2, 2007; Washington, DC.
11. Centers for Medicare & Medicaid Services. Inpatient PPS PC Pricer 2008.5. https://www.cms.gov/PCPricer/03_inpatient.asp. Accessed July 7, 2008.
12. Thompson Healthcare. Red Book. Montvale, NJ: Thompson Healthcare; 2008.
13. Gencarelli DM. One Pill, Many Prices: Variation in Prescription Drug Prices in Selected Government Programs. NHPF Issue Brief. 2005;(807):1-20. http://www.nhpf.org/library/issue-briefs/IB807_DrugPricing_08-29-05.pdf. Published August 29, 2005. Accessed July 15, 2009.
14. Danzon PM, Wilensky GR, Means KE. Alternative strategies for Medicare payment of outpatient prescription drugs-Part B and beyond. Am J Manag Care. 2005;11(3):173-180.
15. Office of the Inspector General (OIG), US Department of Health and Human Services. Medicaid Pharmacy-Additional Analyses of the Actual Acquisition Cost of Prescription Drug Products (A-06-02-00041). http://www.oig.hhs.gov/oas/reports/region6/60200041.pdf. Published September 16, 2002. Accessed July 20, 2009.
16. The National Cancer Institute. PDQ (Physician Data Query) [database]. http://www.cancer.gov/cancertopics/pdq. Accessed July 7, 2009.
17. Kanzler MH. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1999;41(2, pt 1):281-283. Comment on: J Am Acad Dermatol. 1998;38(5, pt 1):669-680.
18. Witheiler DD, Cockerell CJ. Sensitivity of diagnosis of malignant melanoma: a clinicopathologic study with a critical assessment of biopsy techniques. Exp Dermatol. 1992;1(4):170-175.
19. Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317.
20. Bedrosian I, Faries MB, Guerry D 4th, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7(4):262-267.
21. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107(10):2436-2445.
22. Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol. 1998;134(5): 569-572.
23. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA. 1995;274(21):1703-1705.
24. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110(5): 1107-1113.
25. Fader DJ, Wise CG, Normolle DP, Johnson TM. The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad Dermatol. 1998;38(5, pt 1):742-751.
26. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/ C9190. J Clin Oncol. 2000;18(12):2444-2458.
27. Hamm C, Verma S, Petrella T, Bak K, Charette M; Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Biochemo-therapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev. 2008;34(2):145-156.
28. Caracò C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. 2007;14(9):2662-2667.
29. Nashan D, Müller ML, Grabbe S, Wustlich S, Enk A. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-theart in daily routine. J Eur Acad Dermatol Venereol. 2007;21(10):1305-1318.
30. Ransom JW, Rettig T. Specialty drug distribution: robust growth at attractive valuations. Raymond James and Associates, Inc. July 17, 2002. Internal Report.
31. Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs. 2000;14(5):299-318.
32. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961-966.
33. Hanchate A, Kronman AC, Young-Xu Y, Ash AS, Emanuel E. Racial and ethnic differences in end-of-life costs: why do minorities cost more than whites? Arch Intern Med. 2009;169(5):493-501.
34. Bureau of Labor Statistics, US Department of Labor. Table containing history of CPI-U U.S. All items indexes and annual percent changes from 1913 to present. http://www.bls.gov/CPI/#tables. Accessed June 20, 2009.
35. Eagle KA, Garson AJ Jr, Beller GA, Sennett C. Closing the gap between science and practice: the need for professional leadership. Health Aff (Millwood). 2003;22(2):196-201.
36. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993;11(4):638-643.
37. Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2005;19(1):66-73.
38. Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141(3):284-288.
39. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104(3):570-579.
40. Moore P. How do your payers measure up? Physicians Practice website. http://www.physicianspractice.com/display/article/1462168/1586235. Published June 2006. Accessed July 20, 2009.
41. Adams B. Yervoy, Bristol Myers Squibb's new treatment for advanced skin cancer has gained approval in the US. InPharm website. http://www.inpharm.com/news/152647/new-melanoma-drug-approved-fda. Published March 28, 2011. Accessed April 10, 2011.
42. Hellerman C. Skin cancer drug approved early. CNN Health website. http://thechart.blogs.cnn.com/2011/08/17/skin-cancer-drug-approved-early/?hpt=hp_t2. Published August 17, 2011. Accessed August 17, 2011.
43. Miller SC, Intrator O, Gozalo P, Roy J, Barber J, Mor V. Government expenditures at the end of life for short and long-stay nursing home residents: differences by hospice enrollment status. J Am Geriatr Soc. 2004;52(8):1284-1292.
44. Bee PE, Barnes P, Luker KA. A systematic review of informal caregivers' needs in providing home-based end-of-life care to people with cancer. J Clin Nurs. 2009;18(10):1379-1393.
45. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.
46. McMasters KM, Ross MI, Reintgen DS, et al. Final results of the Sunbelt Melanoma Trial. J Clin Oncol. 2008;26(May 20 suppl):abstr 9003.
47. Barnett K. Cancer screening. Lecture given on July 15, 2009, at National Institutes in Health, Bethesda, MD. 2009. ResearchChannel archives. http://www.youtube.com/watch?v=O4XVEBn6BCU. Accessed May 2010.
48. Swerlick RA, Chen S. The melanoma epidemic: is increased surveillance the solution or the problem? Arch Dermatol. 1996;132(8):881-884.
49. Swerlick RA, Chen S. The melanoma epidemic: more apparent than real? Mayo Clinic Proc. 1997;72(6):559-564.
50. Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer. 2006;95(1):91-95.
51. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102(17):6092-6097.
52. Reid RJ, Coleman K, Johnson EA, et al. The group health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood). 2010;29(5):835-843.
53. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009.
54. Whellan DJ, Reed SD, Liao L, Gould SD, O'connor CM, Schulman KA. Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives. Am J Cardiol. 2007;99(2):256-260.